Protection against advanced glycation end products and oxidative stress during the development of diabetic keratopathy by KIOM-79.

Abstract

OBJECTIVES:

KIOM-79 is a mixture of 80% ethanol extracts of parched Puerariae radix, gingered Magnoliae cortex, Glycyrrhizae radix and Euphorbiae radix. The preventive effect of KIOM-79 on the development of diabetic keratopathy has been investigated.

METHODS:

Seven-week-old male Zucker diabetic fatty (ZDF) rats were treated with KIOM-79 (50 mg/kg body weight) once a day orally for 13 weeks. The thickness of the cornea was measured and the extent of corneal cell death was detected by a terminal deoxynucleotidyl transferase dUTP nick-end labelling assay. The expression of advanced glycation end products (AGEs), 8-hydroxydeoxyguanosine, nuclear factor-kappaB (NF-κB), Bax and Bcl-2 were evaluated in corneal tissues.

KEY FINDINGS:

The administration of KIOM-79 prevented corneal oedema and apoptotic cell death of corneal cells. The accumulation of AGE in corneal tissues was reduced in ZDF rats treated with KIOM-79. Moreover, KIOM-79 attenuated oxidative DNA damage, NF-κB activation and Bax overexpression in the cornea.

CONCLUSIONS:

The results suggested that KIOM-79 exhibited corneal protective properties by not only reducing oxidative stress but inhibiting the AGEs/NF-κB downstream signal pathway during the development of diabetic keratopathy.

• Authors: Junghyun Kim, Chan-Sik Kim, Hyojun Kim, Il-Ha Jeong, Eunjin Sohn, Jin Sook Kim
• Journal: The Journal of pharmacy and pharmacology (J Pharm Pharmacol) Vol. 63 Issue 4 Pg. 524-30 (Apr 2011) ISSN: 2042-7158 [Electronic] England
• PMID: 21401604 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society.

Chemical References

• Antioxidants
• Blood Glucose
• Glycation End Products, Advanced
• KIOM 79
• NF-kappa B
• Plant Extracts
• Proto-Oncogene Proteins c-bcl-2
• bcl-2-Associated X Protein
• 8-Hydroxy-2'-Deoxyguanosine
• Deoxyguanosine

Topics

• 8-Hydroxy-2'-Deoxyguanosine
• Animals
• Antioxidants (pharmacology, therapeutic use)
• Apoptosis (drug effects)
• Blood Glucose (metabolism)
• Cell Death (drug effects)
• Cornea (drug effects, metabolism, pathology)
• Deoxyguanosine (analogs & derivatives, metabolism)
• Diabetes Complications (prevention & control)
• Edema (prevention & control)
• Glycation End Products, Advanced (metabolism)
• Male
• NF-kappa B (biosynthesis)
• Oxidative Stress (drug effects)
• Plant Extracts (pharmacology, therapeutic use)
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• Rats
• Rats, Zucker
• Signal Transduction (drug effects)
• bcl-2-Associated X Protein (biosynthesis)